SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company's total revenue for the quarter ended December 2023 saw a slight change in the total revenue, having registered a total revenue of Rs. 8049.80 millions.Net Profit of the company move down -72.27% to Rs. 454.90  millions from Rs. 1640.30 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 2458.50 millions from 2514.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 8049.80 7991.10 0.73 24963.80 24341.80 2.56 32163.40 32175.10 -0.04
Other Income 283.40 236.00 20.08 936.10 735.50 27.27 1015.20 762.20 33.19
PBIDT 2458.50 2514.00 -2.21 7389.50 7062.00 4.64 9009.30 8320.50 8.28
Interest 3.20 0.90 255.56 10.30 11.60 -11.21 18.10 19.90 -9.05
PBDT 822.20 2399.40 -65.73 5919.10 6936.70 -14.67 8981.50 8416.40 6.71
Depreciation 171.10 164.10 4.27 515.80 485.90 6.15 657.70 681.90 -3.55
PBT 651.10 2235.30 -70.87 5403.30 6450.80 -16.24 8323.80 7734.50 7.62
TAX 196.20 595.00 -67.03 1487.20 1718.60 -13.46 2276.80 3968.70 -42.63
Deferred Tax -117.00 -95.10 23.03 -258.30 -176.10 46.68 -183.70 -105.00 74.95
PAT 454.90 1640.30 -72.27 3916.10 4732.20 -17.25 6047.00 3765.80 60.58
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 30.54 31.46 -2.92 29.60 29.01 2.03 28.01 25.86 8.32

Glaxosmithkline Phar Share Price

2419.10 12.85 (0.53%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×